New Jersey Bioscience Center Newsletter

FOURTH QUARTER 2022

Life Sciences Eco-System News in New Jersey

New Jersey is The Best !! Facts About New Jersey's Leadership in BioPharma—Learn more at the Healthcare Institute of New Jersey's website:

- 14 of the world's 20 largest researchbased biopharma companies maintain a headquarters or significant presence in New Jersey.
- 11 of the world's 20 largest medical technology companies maintain a head-quarters or significant presence in New Jersey.
- New Jersey is one of the top two states in the nation for the most facilities manufacturing FDA-approved products.
- #1 state for life sciences manufacturing employees
- #2 state for biotechnology strength.
 New Jersey's biotechnology community
 has grown by more than 400 percent in less than two decades
- #3 NJ/NY regional ranking in the *Genetic Engineering & Biotechnology* News (GEN) top 10 U.S. biopharma clusters list
- NJ has the highest concentration of scientists and engineers per square mile in the U.S.
- #3 state for employed biochemists and biophysicists
- 430,000+ total life sciences-supported jobs (direct and indirect) in New Jersey, representing 10.6 percent of all jobs in the state (as of August 2020)

New Jersey is The Best—Part 2!!
According to Inc. Magazine, five states are the best places to start a business.
New Jersey comes in at #3! Learn more by clicking the following link: https://www.inc.com/minda-zetlin/start-business-best-states-california-texas-new-jersey-illinois-georgia.html

BIOSCIENCE CENTER INCUBATOR AND STEP-OUT LABS AT NORTH BRUNSWICK

NEW JERSEY BIOSCIENCE CENTER

675 US-1, North Brunswick Township, NJ 08902

New Jersey Bioscience Center In The News

Incubator at North Brunswick has a New Resident, Welcome Lactiga!!

Lactiga is a biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases (PID). The company is hoping to unlock the full therapeutic value of human breastmilk to create the next generation of anti-infectives, medicine that inhibits infectious organism spread or kills it. Learn more in this <u>article</u> and on the company's <u>website</u>. Lactiga recently raised \$1.6 million in a pre-seed round and secured \$350,000 in research grants.

BioAegis Therapeutics News

In October, BioAegis Therapeutics Inc., a clinical-stage company developing therapies for infectious, inflammatory, and degenerative diseases was highlighted in an article regarding its research of a human protein that boosts the body's immune system. <u>Link to article here</u>. BioAegis is a current resident of the Step-Out Labs and a graduate of the Incubator at North Brunswick.

Ovster Point Pharma Acquired

Step-Out Labs resident Oyster Point Pharm, is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies to treat ocular surface diseases. The publicly-traded company was recently acquired by Viatris Inc. (Nasdaq: VTRS), a global healthcare company.

A Grant from the OsteoScience Foundation supports research at NJ Bioscience Center –

Osseoprint, a resident of the Incubator at North Brunswick, will benefit from a grant from the OsteoScience Foundation to advance the development of patient-specific, 3D printed bone regeneration scaffolds. The \$100,000 grant has been awarded directly to the principal investigator, Dr. Joachim Kohn, and Osseoprint's Chief Executive Officer Dr. Arthur Greyf. This project aims to develop a workflow that can create 3D-printed bone scaffolds for guided surgery that are patient-matched, aseptically-produced, and immediately implantable. The fundamental innovation of this project is the concept of creating a sterile clean-room within a 3D printer, instead of putting the printer into a clean room or relying on post-printer sterilization. Scaffold production will be in the surgeon's or dentist's office, eliminating the need for shipping the implants from a central facility. The first clinical application of this technology will be by dental implantologists who will use the bone scaffolds to regenerate bone in patients who have significant mandibular or maxillary bone loss prior to the placement of a tooth implant. Dr. John Full, a practicing maxillofacial surgeon and Dr. Pamela Yelick, a Professor of Orthodontics at Tufts School of Dental Medicine are also contributing to the project. Once the research is complete, OsseoPrint 3D, LLC will further support the rapid commercialization of this ground-breaking concept.

Doehler Moves Into New Jersey Bioscience Center

Focused on science, technology and innovation, Doehler shapes the future of nutrition!! To expand its natural flavors business, Doehler, a global producer and marketer of natural ingredients for the food, beverage and nutrition industries, is establishing a new innovation and technology facility at the New Jersey Bioscience Center. The new facility will <u>integrate science-led R&D and</u> innovation work with customer cocreation.

Genomic Prediction Appoints New CEO

Incubator graduate - and current resident of the New Jersey Bioscience Center - Genomic Prediction, recently promoted Kelly Ketterson to CEO. "Kelly's decades of experience successfully leading at other top companies in the industry, and the enormous progress she's made here in her last ten months as COO makes this promotion a natural progression" said Dr. Nathan Treff, Chief Science Officer and Co-founder of Genomic Prediction.

Incubator Labs Available at the New Jersey Bioscience Center Research Park
The Incubator At North Brunswick has several small labs available now.
Email or call Lenzie Harcum (732-839-1880) with any questions.

New Jersey Bioscience Center Newsletter

FOURTH QUARTER 2022

Upcoming Events for NJ's Life Science Community

New Jersey Academic Drug Discovery Consortium on Infectious Diseases -, December 16 from 8:00 a.m. - 3:00 p.m. The New Jersey Academic Drug Discovery Consortium will host the 2022 annual meeting at the Institute for Life Science Entrepreneurship. There will be presentations, networking opportunities, lunch, and poster sessions. David Perlin, Chief Scientific Officer (CSO) and Senior Vice President, from the Center for Discovery and Innovation (CDI) and professor of medical sciences at the Hackensack Meridian School of Medicine will provide the keynote address. Attendees will also hear a scientific program featuring: Jun Wang, Ph.D., and Purnima Bhanot, Ph.D., from Rutgers University, Thomas Dick from CDI-Hackensack Meridian, David Olsen from Merck, and a special presentation from Erin Duffy, Ph.D., CSO of CARBX. Register here.

BIONJ Seventh Annual Patient Advocacy Summit on Tuesday, December 13. Back in person after two years, the Summit will bring together, Patient Advocacy Groups, Caregivers, Clinicians and R&D Professionals. Attendees will gain valuable tools and insights, share best practices and meet key stakeholders within the health care ecosystem. Register here

New Jersey Bioscience Center Alumni News

PDS Biotechnology Fund Raising

PDS Biotechnology Corp. (NASDAQ: PDSB), a graduate of the Incubator at North Brunswick, has filed for a \$150 mixed shelf offering. The company intends to use the proceeds for development and commercialization of product candidates and general corporate purposes. Separately, PDS has entered into a debt financing agreement led by Horizon Technology Finance Corporation for up to \$35 million. PDS is a clinical-stage immunotherapy company developing targeted immunotherapies for cancer and infectious disease. Learn more about the company in this The Fly interview with PDS CEO Frank Bedu-Addo.

Bellerophon Announces New FDA Study

Bellerophon, a graduate of the Incubator at North Brunswick, recently <u>announced U.S. Food and Drug Administration (FDA) Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease.</u> Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies in the treatment of cardiopulmonary diseases

Aucta Pharmaceuticals Announces FDA Approval

Aucta Pharma, a graduate of the Incubator at North Brunswick, recently <u>announced FDA approval of a generic version of Perforomist®</u> (Formoterol Fumarate) <u>Inhalation Solution</u>. Aucta also recently acquired a five building complex in Basking Ridge.

NJ BIO, 2022 Best Contract Research Provider

Incubator at North Brunswick graduate, NJ BIO, a contract research organization providing integrated chemistry and biology services, was recently awarded Best Contract Research Provider at the 2022 World ADC (Antibody Drug Conjugate) Awards. NJ BIO now occupies an 80,000 SF former BMS facility. The company is currently https://doi.org/10.1007/journal.org/

Advaxis Merges with Ayala Pharmaceuticals

Incubator at North Brunswick graduate, Advaxis, a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, recently announced that it entered into a <u>merger with Ayala Pharmaceuticals</u>. Advaxis is based in Monmouth Junction, NJ.

Funding, Grants & Incentives for Life Science Companies

A List of The 24 Companies That Received \$75 Million in 2022 NOL Awards

The New Jersey Economic Development Authority's (NJEDA's) Net Operating Loss Program enables eligible early-stage technology and life sciences businesses in the Garden State to sell a percentage of their New Jersey net operating losses and unused research and development (R&D) tax credits to unrelated profitable corporations for cash. The average 2022 award was over \$3.1 million. Three of this year's awardees, Bellerophon, Advaxis and PDS Biotech, are graduates of the Incubator at North Brunswick. A fourth, AIM ImmunoTech, is a current resident of the New Jersey Bioscience Center. Read about all 24 companies here.

New Jersey Manufacturing Voucher Program Launched

New Jersey Manufacturers Voucher Program (NJ MVP) will provide equipment grants sized at 30 percent – 50 percent of the cost of the eligible equipment (including installation) up to a maximum award amount of \$250,000. Most biotech companies are eligible to apply for the NJEDA's \$250,000 manufacturing voucher program. NJMVP will offer stackable bonuses for certified woman-, minority-, or veteran-owned businesses, businesses in Opportunity Zones, and businesses purchasing manufacturing equipment in New Jersey. An information webinar was conducted in November – a recording of the webinar can be accessed here.

Innovation and Research Fellowship Program Grants

Innovation and Research Fellowship Program (IRFP) funds are designed to encourage Ph.D. graduates to continue their research in fellowship with New Jersey based scientific companies. The IRFP grant monies shall be used by the grantee employer primarily as salary for the Fellow. The application for an IRFP grant must be completed and submitted jointly by the applicant employer and the applicant Fellow. See more on the NJDOL website. Application Deadline: Monday, January 23, 2023, by 3:00 p.m. Link to PDF Here.

Big Funding News In NJ

New Jersey's PTC Therapeutics Will Receive Up To \$1B from Blackstone to Accelerate Pipeline

